Clinical Trials Logo

Clinical Trial Summary

A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist


Clinical Trial Description

This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate efficacy and safety of tralokinumab administered subcutaneously in subjects with uncontrolled asthma on inhaled corticosteroid plus long-acting β2-agonist and having a history of asthma exacerbations. Approximately 770 subjects will be randomized globally. Subjects will receive tralokinumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02194699
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 3
Start date October 30, 2014
Completion date September 21, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT06029595 - Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy Phase 2
Active, not recruiting NCT03978936 - Medication Adherence With Telehealthcare Medication Therapy Management N/A
Active, not recruiting NCT06448585 - Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. Phase 4
Completed NCT02161757 - A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma Phase 3
Completed NCT02768623 - Evaluation of a Community Pharmacist Managed Asthma Consultation Service N/A
Completed NCT02906761 - Aspirin for Uncontrolled Asthma Phase 3
Completed NCT04865575 - Systems Pharmacology Approach to Uncontrolled Pediatric Asthma